During the last session, Neumora Therapeutics Inc. (NASDAQ:NMRA)’s traded shares were 0.31 million. At the end of the trading day, the stock’s price was $11.26, reflecting an intraday gain of 0.18% or $0.02. The 52-week high for the NMRA share is $21.00, that puts it down -86.5 from that peak though still a striking 26.02% gain since the share price plummeted to a 52-week low of $8.33. The company’s market capitalization is $1.80B, and the average intraday trading volume over the past 10 days was 0.76 million shares, and the average trade volume was 834.48K shares over the past three months.
Neumora Therapeutics Inc. (NMRA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. NMRA has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.4.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Neumora Therapeutics Inc. (NASDAQ:NMRA) trade information
Neumora Therapeutics Inc. (NMRA) registered a 0.18% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.18% in intraday trading to $11.26, hitting a weekly high. The stock’s 5-day price performance is -9.99%, and it has moved by -2.51% in 30 days. The short interest in Neumora Therapeutics Inc. (NASDAQ:NMRA) is 8.86 million shares and it means that shorts have 6.1 day(s) to cover.
The consensus price target of analysts on Wall Street is $24.5, which implies an increase of 54.04% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20 and $29 respectively. As a result, NMRA is trading at a discount of -157.55% off the target high and -77.62% off the low.
Neumora Therapeutics Inc. (NMRA) estimates and forecasts
Statistics show that Neumora Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Neumora Therapeutics Inc. (NMRA) shares have gone down -35.47% during the last six months, with a year-to-date growth rate more than the industry average at 59.23% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 64.90% this quarter and then jump 45.10% in the quarter after that.
While earnings are projected to return 59.28% in 2024.
NMRA Dividends
Neumora Therapeutics Inc. is due to release its next quarterly earnings 2024-Aug-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Neumora Therapeutics Inc. (NASDAQ:NMRA)’s Major holders
Neumora Therapeutics Inc. insiders own 28.05% of total outstanding shares while institutional holders control 54.70%, with the float percentage being 76.03%.
Also, the Mutual Funds coming in first place with the largest holdings of Neumora Therapeutics Inc. (NMRA) shares are iShares Russell 2000 ETF and Price (T.Rowe) Small-Cap Value Fund . Data provided on Jun 30, 2024 indicates that iShares Russell 2000 ETF owns about 2.0 shares. This amounts to just over 1.25 percent of the company’s overall shares, with a $22.55 million market value. The same data shows that the other fund manager holds slightly less at 1.02, or about 0.64% of the stock, which is worth about $11.49 million.
